[go: up one dir, main page]

PL2310044T3 - Immunoterapia przeciwnowotworowa - Google Patents

Immunoterapia przeciwnowotworowa

Info

Publication number
PL2310044T3
PL2310044T3 PL09776746T PL09776746T PL2310044T3 PL 2310044 T3 PL2310044 T3 PL 2310044T3 PL 09776746 T PL09776746 T PL 09776746T PL 09776746 T PL09776746 T PL 09776746T PL 2310044 T3 PL2310044 T3 PL 2310044T3
Authority
PL
Poland
Prior art keywords
tumor immunotherapy
immunotherapy
tumor
Prior art date
Application number
PL09776746T
Other languages
English (en)
Inventor
Gilberto Filaci
Francesco Indiveri
Paolo Traverso
Original Assignee
Mediolanum Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici S.P.A. filed Critical Mediolanum Farmaceutici S.P.A.
Publication of PL2310044T3 publication Critical patent/PL2310044T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL09776746T 2008-06-16 2009-06-16 Immunoterapia przeciwnowotworowa PL2310044T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6177808P 2008-06-16 2008-06-16

Publications (1)

Publication Number Publication Date
PL2310044T3 true PL2310044T3 (pl) 2017-04-28

Family

ID=41507473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09776746T PL2310044T3 (pl) 2008-06-16 2009-06-16 Immunoterapia przeciwnowotworowa

Country Status (14)

Country Link
US (1) US8828403B2 (pl)
EP (1) EP2310044B1 (pl)
JP (1) JP5787752B2 (pl)
CA (1) CA2727388C (pl)
CY (1) CY1118215T1 (pl)
DK (1) DK2310044T3 (pl)
ES (1) ES2602453T3 (pl)
HR (1) HRP20161434T1 (pl)
HU (1) HUE030984T2 (pl)
LT (1) LT2310044T (pl)
PL (1) PL2310044T3 (pl)
PT (1) PT2310044T (pl)
SI (1) SI2310044T1 (pl)
WO (1) WO2010003520A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2536830T1 (sl) 2010-02-16 2019-12-31 Ultimovacs As Polipeptidi
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2875824B1 (en) 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Composition for preventing or treating cachexia
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
KR102544207B1 (ko) * 2012-09-19 2023-06-16 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN104768967B (zh) * 2012-09-19 2019-02-15 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102093093B1 (ko) * 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
JP6495899B2 (ja) * 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
WO2015023132A1 (ko) * 2013-08-14 2015-02-19 주식회사 카엘젬백스 다발성 경화증 치료 및 예방용 조성물
BR112016008331B1 (pt) * 2013-10-23 2023-01-31 Sang Jae Kim Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp
KR102307567B1 (ko) * 2013-11-12 2021-10-01 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
JP6367950B2 (ja) * 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
ES2886946T3 (es) 2015-07-02 2021-12-21 Gemvax & Kael Co Ltd Péptido con efecto antiviral y composición que lo contiene
CN117018162A (zh) 2016-04-07 2023-11-10 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及组合物
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
JP7628220B2 (ja) 2021-09-24 2025-02-07 チャ ワクチン リサーチ インスティテュート カンパニー リミテッド 腫瘍関連抗原に由来するペプチド及びリポペプチド及び免疫活性物質からなるアジュバントを含む抗がんワクチン組成物、並びにその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0105238D0 (en) 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
AU2002363231A1 (en) 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi

Also Published As

Publication number Publication date
US8828403B2 (en) 2014-09-09
EP2310044A2 (en) 2011-04-20
WO2010003520A3 (en) 2010-07-15
HRP20161434T1 (hr) 2017-02-24
US20110135692A1 (en) 2011-06-09
HUE030984T2 (en) 2017-06-28
SI2310044T1 (sl) 2017-03-31
PT2310044T (pt) 2016-11-18
CA2727388C (en) 2017-08-29
CY1118215T1 (el) 2017-06-28
WO2010003520A2 (en) 2010-01-14
ES2602453T3 (es) 2017-02-21
JP5787752B2 (ja) 2015-09-30
LT2310044T (lt) 2016-12-27
CA2727388A1 (en) 2010-01-14
JP2011524390A (ja) 2011-09-01
DK2310044T3 (en) 2016-12-12
EP2310044B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
SI2310044T1 (sl) Proti-tumorska imunoterapija
IL210818A0 (en) Gemstone viewer
WO2010080124A9 (en) Nkg2d-fc for immunotherapy
EP2323928A4 (en) CARRIER ASSEMBLY
IL208990A0 (en) Novel phenylimidazopyrazines
GB0815216D0 (en) Interleukin
EP2056861A4 (en) IMPF-IMMUNOTHERAPY
GB2451357B (en) Ceramic Armour
HK1132673A1 (en) Novel methods
GB0811360D0 (en) Methods
GB0818650D0 (en) Methods
GB2471221B (en) Methods
IL207958A0 (en) Allogeneic cancer cell - based immunotherapy
HK1149235A1 (en) Fixture means
EP2161998A4 (en) NOVEL PROCEDURE
GB0817482D0 (en) No-catch zip
GB0812589D0 (en) Adoptive immunotherapy
GB0711729D0 (en) Adoptive immunotherapy
GB0712715D0 (en) Adoptive immunotherapy
AU2008903232A0 (en) Cancer immunotherapy
AU2009903449A0 (en) Cancer Immunotherapy
PH32008000431S1 (en) Gemstone
PH32008000422S1 (en) Gemstone
GB0811114D0 (en) Mud-monster + tail-safe
GB201019672D0 (en) Decorative mirror fixings